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ABSTRACT
￿
While a multiplicity of cellular and biochemical effects are mediated by inteferons
on cultured cells, the mechanisms involved in the direct growth-inhibitory activity of interfer-
ons remain problematic. We have previously found that variants in CAMP metabolism in a
macrophage cell line, J774.2, were at least 50-fold less sensitive to the growth inhibitory
activity of interferons (IFN) than the parental clone. To test the hypothesis that CAMP mediates
the growth inhibition produced by IFN in these cells, interferon-resistant variants were selected
and characterized with respect to CAMP synthesis and function. Approximately one-third of
the IFN-resistant clones were found to be resistant to growth inhibition produced by cholera
toxin, but not 8Br-CAMP. IFN was fully able to protect all of the interferon-resistant/cholera-
toxin-resistant (IFN`/CTr) clones against infection by vesicular stomatitis virus and markedly
stimulated 2', 5'-oligodenylate synthetase activity. These IFN`/CTr variants were shown to
have a defect in adenylate cyclase. The remaining IFN-resistant clones were fully susceptible
to the growth-inhibitory effects of cholera toxin because their basal and stimulated adenylate
cyclase activity is similar to that of the parental clone. IFN failed to protect these IFNr/cholera-
toxin sensitive clones against infection by vesicular stomatitis virus and failed to stimulate 2',
5-oligodenylate synthetase, suggesting that they have defective or deficient IFN receptors. In
addition, IFN failed to increase intracellular CAMP levels in both IFNr/CTr and IFNr/cholera-
toxin sensitive clones. These results provide firm genetic and biochemical evidence that the
growth inhibitory effects of IFN on this cell line are mediated by CAMP.
Interferons (IFN)' exert a variety of biological effects in ad-
dition to their antiviral activity. They inhibit cell growth of
primary and transformed cells (1-4), modify thymidine trans-
port (5), induce the synthesis of specific enzymes, such as
2',5'-oligoadenylate synthetase (6) and a CAMP-independent
protein kinase (7), altercytoskeletal and morphological prop-
erties of cells (8), and increase intracellular levels of CAMP
(9). In studies of the effects of IFN on cells of the immune
system, we and others have observed an increase in Fc recep-
tor mediated phagocytosis in macrophages or macrophage-
1 Abbreviations used in this paper: CT`, cholera-toxin resistant clones;
CTI, cholera-toxin sensitive clones; GppNHp, guanyl-5'-imidodi-
phosphate; IFN, interferons; IFN`, interferon-resistant clones; VSV,
vesicular stomatitis virus.
like cell lines, similar to that induced by treatment with CAMP
(10-12). Upon exposure to IFN the intracellular concentra-
tion of CAMP increased concomitantly with phagocytosis.
Further IFN failed to augment Fc receptor-mediated phago-
cytosis in adenylate cyclase and CAMP-dependent protein
kinase variants selected from a macrophage-like cell line,
J774.2, although it conferred full antiviral protection (12).
These variants in CAMP synthesis and function in J774.2
were also resistant to IFN-mediated growth inhibition. If
CAMP mediates the growth-inhibitory effect of IFN on cells,
then one would predict that among clones selected for resist-
ance to the growth inhibitory effects of IFN variants in
adenylate cyclase or CAMP-dependent protein kinase activi-
ties would be found. Confirmation ofthis prediction is herein
presented.
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Cells:
￿
The cloned cell line J774.2 was originally established from mouse
reticulum cell sarcoma derived by P. Ralph et al. (13) and shown to have a
macrophage like phenotype (14, 15). Cells were maintained in Dulbecco's
modified Eagle's medium (DME, Gibco Laboratories, Grand Island, NY)
supplemented with 20% heat-inactivated horse serum (Gibco Laboratories),
10% NCTC 109 medium (Microbiological Associates, Walkersville, MD), 0.1
mM nonessential amino acids (NEAR, Gibco Laboratories), I mM sodium
pyruvate, penicillin, and streptomycin at 37°C in a humid incubator containing
5% C02-
The mouse hepatoma cell line, E,, was incubated in Dulbecco's modified
Eagle's medium supplemented with 10% heat-inactivatedfetal calfserum (FCS,
Gibco Laboratories), 5% NCTC, and I % NEAA and trypsinized once a week.
Primary rat embryo fibroblasts (REF) were cultured in Dulbecco's modified
Eagle's medium supplemented with 10% fetal calf serum (Gibco Laboratories).
Interferon:
￿
Mouse IFN (IFN a + 0, specific activity 1 .3 x 10' IU/mg
protein) was purchased from Lee Biomolecular Research Laboratories (San
Diego, CA) and IFN a from Enzo Biochemicals (New York, NY). The specific
activitiesforantiviral activity ofthesepreparations establishedin thislaboratory
were 6.5 x 10' U/mg and 5 x 108 U/mg, respectively assayed by inhibition of
cytopathic effects ofvesicular stomatitis virus (VSV) on L cells (16).
Vesicular Stomatitis Virus:
￿
The Indiana (HRC) serotype of VSV
was prepared in chicken embryo fibroblasts, clarified by centrifugation (1,000
g, 10 min), and frozen at -70°C. This stock contained 5 x 10' pfu/ml ofVSV.
For use, this stock was diluted in Dulbecco's modified Eagle's medium with
2% fetal calf serum.
Selection of IFN-resistant Variants:
￿
Cells were cloned in soft agar
in 60-mm tissue culture dishes (Falcon A 3002; Falcon Labware, Oxnard, CA)
above E, or rat embryo fibroblasts feeder layers (14, 17). A solution of 0.5%
agarose (wt/vol) (Sea Plaque, Marine Celloids, Inc., Rockland, MD) in mac-
rophage growth medium was layered onto the feeder layer and solidified at 4°C
for 10 min. The cells to be cloned (2,000 cells/plate) were suspended in I ml
of0.43% agarose in medium. The dishes were again cooled at 4°C for 10 min
and then placed in a 37°C incubator.
For selection of IFN-resistant variants, each independently derived clone
was recloned 4-5 times in increasing concentrations ofIFN, ranging from 500
U/ml to 5,000 U/ml over 6 mo period. All variants remained stable when
grown for 3 mo in the absence ofIFN.
Growth Curves:
￿
Cells to be tested (0.5-1 x 10° were seeded in 1 ml
ofmedium in 2.0 cmZ tissue culture wells (Linbro) in the presence or absence
of IFN, 8Br-cAMP, or cholera toxin (Schwarz Mann, Orangeburg, NY). At
appropriate times, cells were harvested and cells excluding trypan blue were
counted. On day 3 each well was fed with 0.5 ml of media containing the
appropriate drug.
Preparation of Cell Membrane Extracts: Plasma membranes
were prepared according to the procedures devised by Neville (18). Cells (4-5
x 10')grown to confluence werecollected, washedin phosphate buffered saline,
pH 7.4, and sedimented at 200 g for 10 min. The cells (1.5 x 106/ml) were
then resuspended in a dounce buffer containing 5 mM Tris-HCl, pH 7.8, 5
mM NaCl, 0.1 mM EGTA, and I mM dithiothreitol and incubated in ice for
3 min. MgCIZ was added to a final concentration of 5 mM and the cells
incubated for 2 min. They were then dounced with 45 strokes in a tight
homogenizer, centrifuged at 400 g and the supernatant fluids were collected.
The pellets weredounced with additional 25 strokesin a small volume ofbuffer
and the supernatant fluids combined, centrifuged at 40,000 g for 15 min and,
washed with dounce buffer (dithiothreitol was excluded) under the same
conditions. Protein was determined by the method of Lowry et al. (19) using
bovine serum albumin as a standard. Membranes were stored at 1.2 mg/ml at
-70°C and thawed only once.
Adenylate Cyclase Determinations:
￿
Reaction mixtures consisted
ofcell membrane protein, 25 mM Tris-HCl buffer, pH 7.5, 5 mM MgCIZ, 0.5
mM dithiothreitol, 10 mM creatine phosphate, 0.5 U of creatine phosphoki-
nase, 1 mM cAMP, 0.5 MM a-["PI ATP (4.2-10.2 cpm/pmol) in a volume of
55 ul. Guanyl-5'-imidodiphosphate (GppNHp) (100 AM), NaF (20 mM), or
isoproterenol (60 uM) were added as indicated. The reaction was carried out at
37'C for 15 min and stopped by addition of 100 Al ofa solution containing2%
sodium dodecylsulfate and, 40 mM ATP, pH 7.5, (Amersham Corp., Arlington
Heights, IL). 'H-cAMP (approximately 20,000 cpm) was added to monitor
recovery. cAMP was isolated according to the method ofSalomon et al. (20).
Intracellular cAMP Determinations: cAMP was measured by
displacement of 'H-cAMP from a preparation of cAMP binding protein as
described in (21). Cells (I x 10') were washed with saline and extracted (1 ml/
100-mm dish) with 50% glacial acetic acid. The cAMP binding assay was
carried out for 1 .5 h in ice, stopped by adding ammonium sulfate (3.8 M, final
concentration) and the reaction mixturewas filtered (Schleicherand Schell GF/
C filters) and counted as described (21). The assay was calibrated for 0.25 to
3.0 pmol cAMP. Cholera toxin (100 ng/ml or 300 ng/ml) was added to the
medium2 h and IFN (1,000 or 2,000 U/ml) 20 hbefore the cellswere harvested.
Infection with VSV:
￿
Cells(2 x 105)were plated in2-cm'wells(Linbro)
for 24 h in 1 ml of medium, and IFN was then added for an additional 24 h.
VSV, at multiplicities of infection of 0.12 and 0.012 was added and the cells
cultured for 48 h. Supernatants were collected and stored frozen at -70°C.
Cells were fixed with formol-saline for 10 min and stained with crystal violet
for 20 min. Cytopathic effects were expressed as percentage ofeach stained cell
monolayer destroyed.
Viral Yields:
￿
Serial 10-fold dilutions (0.2 ml) ofthe above supernatant
fluids were added to confluent Vero cell monolayers in 2-cmZ wells. After l h
adsorption at 37°C, I ml ofwarm medium containing 1 % agar was added, and
wells were incubated for an additional 48 h. The monolayers were then fixed,
stained with crystal violet, and virus plaques were counted.
Assay of 2',5'-oligoadenylate Synthetase Activity:
￿
2',5'-
oligoadenylate synthetase activity was assayed by the method described by
Gupta et al. (22). The cells were cultured for 10 h with or without 500 U of
IFN. The cells were extracted with 0.5% NP40, clarified, and the supernatant
fluids frozenat -70°C. 'H-ATP (I mCi/ml, spact 52.6 Ci/mmol)was repurified
on DEAE cellulose and adjusted to a final concentration of 8 mM with cold
ATP.
Cell extracts were applied to 50 tAl ofpoly(1):poly(C) agarose columns (P. L.
Biochemicals, Inc., Milwaukee, WI), and washed with 25 ml of 10 mM HEPES,
pH 7.5, 90 mM KCI, 1 .5 mM magnesium acetate, 7 mM ß-mercaptoethanol,
20% glycerol, and three times with 100 ,u1 of cold reaction mixture (containing
the same buffer and 5 mM ATP, 0.2% creatine phosphate, and 0.03% creatine
phosphokinase) followed by the same mixture containing purified 'H-ATP.
The column was incubated at 30°C for 16 h and 2',5'-A was eluted and boiled
for 3 min. The2',5'-A wasseparatedfrom unconvertedATPon DEAE columns
by elution with buffer containing 350 mM KCl at pH 7.5.
RESULTS
Isolation of IFN-Variants
In initial experiments it was established that the parental
macrophage clone, J774.2, was sensitive to growth inhibition
by IFN. Growth was inhibited at 500 U/ml, and the culture
was killed over a 5-d period by 2,000-4,000 U/ml of IFN
(Fig. 1). To select for IFN-resistant variants, cellswere cloned
in medium containing 5,000 IFN without prior mutagenesis.
Fewer than 10 clones appeared per 2,000 cells plated. Each
clone was isolated and tested for cell growth in the presence
of various concentrations of IFN, along with the parental
J774.2 clone. Those primary clones that were resistant to IFN
were picked and grown in sucessively increasing concentra-
tions ofIFN, 1,000, 3,000, and ultimately 5,000 U/ml over 6
mo. From this selection, 15 independent resistant (IFN`)
clones were obtained. The growth characteristics of some of
these variants in the presence of IFN are shown in Fig. 1 . All
grew in medium containing 4,000 U/ml ofIFN.
To test the prediction that some IFN` clones would be
defective in adenylate cyclase or cAMP-dependent protein
kinase activity, the growth ofthe IFNr clones in the presence
of cholera toxin was examined. Two classes of IFN` variants
were found, cholera toxin resistant (CT') and cholera toxin
sensitive clones (CTS). Clones 68, 82, 92, and 103 were cholera
toxin resistant. Clones 95, 97, 99, and 100 were as sensitive
to cholera toxin as the parental J774.2 clone.
To explore the possibility that some IFN`/CT' clones were
defective in cAMP-dependent protein kinase, the effect of
8Br-cAMP on the growth of these clones was examined. All
were as growth inhibited by 50-100 uM 8Br-cAMP (in the
presence or absence of 0.05 mM of 1-methyl-3-isobutylxan-
thine) as the parental cell line (J774.2). These results suggested
that some IFN`/CT clones might be defective in adenylate
cyclase, but not in cAMP-dependent protein kinase.
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FIGURE 1
￿
Effect of IFN and cholera toxin on growth of wild type
J744.2 and IFN' clones. Cells were plated at 0.5-1 x 104/1 ml in
medium alone (") or in the presence of varying concentrations of
either IFN (O) or cholera toxin (A). Fresh IFN was added on day 3 .
Adenylate cyclase activity in crude membranes of the IFN'
clones was measured following stimulation with GppNHp,
fluoride, or isoproterenol (Table I). Basal adenylate cyclase
activity of the parental clone (J774.2) was stimulated 15-18-
fold by GppNHp or fluoride and 6-fold by isoproterenol. In
contrast, all of the IFN'/CT` variants had reduced basal and
stimulated adenylate cyclase activity. The IFN'/CTS variants
showed similar activities to the parental clone. The addition
ofIFN for 2 h directly to the membrane preparations did not
affect adenylate cyclase activity (data not shown).
The adenylate cyclase activity of both J774.2 and clone 82,
an IFN'/CT' variant, was proportional to the amount of
membrane protein added, up to 50 jug (Fig. 2). When mem-
branes prepared from a mixture of J774.2 and clone 82 were
TABLE I
Adenylate Cyclase Activity in Wild Type and IFN' Clones
GppNHp, fluoride, or isoproterenol were added to the reaction mixture at
the final concentrations of 100, 20, and 60 ,AM, respectively.
PROTEIN (wp)
FIGURE 2
￿
Adenylate cyclase activities in wild type J774.2 and IFN'/
CT' variant 82. Various concentrations of membrane protein were
added with (O) or without (") 100 mM GppNHp in the reaction
mixture.
analyzed, the adenylate cyclase activity was additive, indicat-
ing that the diminished activity of clone 82 could not be
attributed to a diffusible inhibitor of adenylate cyclase (data
not shown).
Intracellular CAMP Levels in Variant Cells
To obtain an indication of the nature of the defect in
adenylate cyclase activity in the IFN'/CT' clones, intracellular
CAMP levels were measured in cell extracts (Table II). Expo-
sure to 100 ng/ml ofCT augmented cAMP levels significantly
in J774.2 and in the IFN'/CTS clones, 95, 99, and 100.
However, the IFN'/CT' resistant clones 82, 68, and 103 failed
to show a response to cholera toxin, although the basal cellular
CAMP levels were not strikingly different from the other
clones. When intracellular levels of the parental and mutant
clones were measured following esposure to 1,000 U of IFN,
as expected there was a 2-3-fold stimulation in J774.2 as
reported previously (12), with essentially no stimulation in
the IFN'/CT' or IFN'/CTS mutants (Table III). The results
from the assays of adenylate cyclase in vitro combined with
the measurements of cellular CAMP content suggest a lesion
Type Clone
cAMP
No addn
(pmol/15 min/50 kg
GppNHp F-
protein)
Isoproter-
enol
Wild type J774.2 2.65 41 .22 47.40 15.75
IFN'/CT' 82 0.73 7.94 29.08 0.82
68 0.26 1 .33 3.87 1 .82
92 0.04 10.01 12.31 1 .53
IFN'/CT' 95 2.10 24.90 45.77 21 .68
97 14.76 108.42 78.87 60.88
99 4.12 56.06 29.81 10.70
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Stimulation of Intracellular CAMP by Cholera Toxin
Cholera toxin was added at 100 and 300 ng/ml for 2 h before cell harvest.
The results depicted are the average of 2 or 3 0774.2) independent experi-
ments, each performed in triplicate. CAMP (pmol/mg protein).
TABLE III
Stimulation of Intracellular cAMP by Interferon
IFN was added at 1,000 U/ml 20 h prior to cell harvest. The results represent
the average of two experiments, each carried out in triplicate, except for
clones 95 and 99 which represent a single experiment performed in tripli-
cate. In one experiment with IFN present at 2,000 U/ml the level of cAMP
in the parental cells was increased to 23.6 pmol/mg protein, similar to that
observed with 1,000 U/ml (20.1 pmol/ml protein). In contrast 2,000 U/ml
of IFN failed to increase the level of cAMP in any of the mutants.
* 1,000 U/ml.
in the regulatory, guanine nucleotide-binding component of
the adenylate cyclase, rather than in the catalytic moiety of
the enzyme.
Antiviral Effects of /FN on lFNr Variant Clones
The most obvious mechanisms for resistanceofthese clones
to the growth inhibitory effects of IFN are a lack of receptors
for IFN, defective adenylate cyclase activity, or both. The
simplest available method to discriminate between these pos-
sibilities was to test for antiviral effects of IFN. This effect is
receptor-mediated and we have shown it to be CAMP inde-
pendent in these cells (12). The antiviral activity of IFN was
determined both by protection against the cytopathic effects
of VSV and by measuring viral yields of IFN treated clones
(Table IV). IFN (10 U/ml) protected the parental clone,
1774.2, and IFNr/CT' variants 82 and 68 against the cyto-
pathic effects of VSV. In contrast, IFN'/CTS clones, 95, 99,
97, and 100 were resistant to the antiviral effects of IFN.
This distinction was confirmed in more quantitative terms
when viral yields were examined (Table IV). Infection of the
Vero cells with VSV at multiplicities of -0.12 and 0.012
revealed that the IFNr/CTr variants were as, or more resistant
to the antiviral effects of IFN as the parental clone. Their
responsiveness formally established the conclusion that these
cells expressed receptors for IFNa. In contrast, the IFN'/CTS
clones failed to demonstrate antiviral activity produced by
IFN. The simplest interpretation is that these clones are
growth resistant to IFN because they lack receptors for IFN.
While chemically pure murine IFNa was not available for
receptor binding studies, this conclusion was supported by
examining 2',5'-oligoadenylate synthetase activity following
IFN treatment. As shown in Table V, IFN caused a marked
increase in 2',5'A synthetase activity in the parental cells and
in the IFNr/CTr clones, but failed to stimulate 2',5'A synthe-
tase activity in the IFNr/CTS clones 95 and 99.
TABLE IV
CPE and Virus Yields in Wild Type and IFN' Clones
10 95 60 1 .2x106 0.2x106
102 ￿90
￿
50
￿
1 .6 x 106
￿
0.3 x 106
103 ￿90
￿
60
￿
1 .7 x 106
￿
0.6 x 106
Cells (2 x 105/ml) were incubated for 48 h with the concentrations of IFN
indicated. They were then infected with VSV and cultured for an additional
48 h. After the supernatants were collected, cells were fixed, stained, and
cytopathic effects were assessed. For assay of virus yields, 0.2 ml of diluted
48-h supernatants were titered on confluent Vero cell monolayers. After 1 h
adsorption at 37°C, 1 ml of medium containing 1% agar was overlayed and
the plates incubated for 48 h. The cells were fixed, stained, and VSV plaques
were counted.
TABLE V
Induction of 2',5'-Oligoadenylate Synthetase Activity after IFN
Treatment
Nanomoles ATP converted per milligram protein.
= 5,000 JA/Ml.
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Clone Phenotype
IFN
treat-
ment
CPE
0.12 0.012
Yields
0.12 0.012
1U/ml % pfu
1774.2 Wild type None 100 100 3.1 x 106 0.7 x 106
10 75 60 90 x 103 6.5 x 103
102 25 10 1 .1 x 103 0.05 x 103
103 0 0 0.75 X 103 0.04 X 103
82 1FN'/CT' None 30 5 3.5 x 106 0.9 x 106
10 0 0 6.5x103 5.0X103
102 0 0 5.0 x 103 0.15 x 103
103 0 0 3.5 x 103 0.35 x 103
68 1FN'/CT' None 75 15 3.0 x 106 0.3 x 10'
10 55 0 7.0 x 103 5.0 x 103
102 30 0 6.5 x 103 10
103 0 0 5.5 x 103 10
95 IFN'/CTs None 90 90 5.5 x 106 1 .7 X 106
10 90 75 1 .5x106 0.3x106
102 80 60 1 .2 X 106 0.8 X 106
103 80 60 1 .0 x 106 0.4 x 106
99 IFN'/CTs None 95 60 1 .4 x 106 0.5 x 106
Clone Phenotype Basal
Cholera
100 ng/ml
toxin
300 ng/ml
J774.2 wt 11 .0 16.6 21 .8
82 IFN'/CT' 8.0 4.5 7.1
68 6.8 5.4 9.6
103 7.4 6.3 5.5
95 IFN'/CTs 9.4 11 .6 20.3
99 7.0 56.9 43.0
100 9.2 42.2 29.8
CTRMl ad cyc- 9.2 14.5 13.6
Phenotype Clone
cAMP (pmol/mg
Basal
protein)
IFN*
Wild type 1774.2 7.8 20.1
IFN'/CT' 82 6.3 4.4
68 4.9 4.9
IFN'/CTs 95 5.6 7.5
99 5.5 8.9
100 4.6 6.3
Clone Phenotype
2',5'-Oligoadenylate
tase
-
synthe-
activity*
IFN*
1774.2 Wild type 21 .8 201 .3
68 IFN'/CT' 17.5 148.5
82 IFN'/CT' 12.5 128.1
95 IFN'/CTs 16.5 22.0
99 IFN'/CTs 22.5 28.0DISCUSSION
Because ofthe multiplicity of cellular and biochemical effects
of interferons on cultured cells, it has been very difficult to
delineate those involved in the direct growth inhibitory activ-
ity of interferons. We have previously observed that although
IFN augmented Fc-receptor mediated phagocytosis in the
J774.2 macrophage line used for these studies, it failed to do
so in variants defective in adenylate cyclase or cAMP-depend-
ent protein kinase derived from this clone (12). Of more
general interest was the finding that these variants in cAMP
metabolism were at least 50-fold less sensitive to the growth
inhibitory activity ofIFN than the parental clone. In contrast,
both the parental and variant clones were fully sensitive to
the antiviral erects of IFN. These experiments suggested that
the inhibitory effects ofIFN on cell growth might be mediated
by cAMP.
The present experiments were undertaken to test that hy-
pothesis using a genetic approach. We argued that if CAMP
mediated the growth inhibition produced by IFN, among
variants selected for resistance to this growth inhibition would
be clones defective in either cAMP synthesis or function.
Accordingly, J774.2 cells resistant to the growth inhibitory
effects of IFN were selected, and 15 independent clones,
capable of growing in concentrations of 4,000 U/ml ofIFNa
were characterized. One third (5/15) ofthese clones were also
resistant to growth inhibition produced by cholera toxin.
None of the clones was resistant to growth inhibition by 8Br-
cAMP. Since growth inhibition by 8Br-cAMP is mediated by
cAMP-dependent protein kinase (23), this enzyme activity
must be both present and normally sensitive to cAMP in the
CT'/CT' resistant cells. This suggested a defect in either the
receptor for cholera toxin or the adenylate cyclase.
When the adenylate cyclase activity of the IFNr/CTr clones
was examined in vitro, the variants had reduced basal activity
as well as marked reduction in GppNHp, F', or isoproterenol-
stimulated activities. Although these cells had normal basal
levels of cAMP, they failed to show an increase in response
to cholera toxin or IFN. Thus many of the clones selected for
resistanceto the growth inhibitory activity of IFN (IFN'/CTr)
have a defect in adenylate cylcase activity, most likely in the
guanine nucleotide-binding component. This appears to be
the same kind of defect found in cells selected for cholera
toxin resistance in these (14, 24) or other cell lines (25, 26).
The remaining IFNr clones were susceptible to the growth
inhibitory effects of cholera toxin and possessed adenylate
cylcase activity similar to that of the parental clone. The most
likely explanation for theirresistanceis a loss ofIFN receptors,
a defect reported previously for other IFN-resistant cells (27).
Since pure murine IFNa was not available for receptor
binding analysis, we assessed receptor function by assaying
for IFN-induced protection against virus infection and stim-
ulation of 2',5'-oligoadenylate synthetase activity. IFN pro-
tected all of the IFN`/CTr clones against infection by VSV
and markedly stimulated 2',5'-oligoadenylate synthetase ac-
tivity, establishing both the integrity of their IFN receptors
and the independence of the antiviral and cell growth inhibi-
tory effects of IFN. Not unexpectedly, IFN afforded little
antiviral protection for the IFNr/CTS clones, supporting the
interpretation that these cells have defective or deficient IFN
receptors. This conclusion was strengthened by showing that
IFN failed to stimulate 2',5'-oligoadenylate synthetase, an
enzyme known to be closely coupled to IFN receptors in all
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cells studied (6). The possibility, however, that they may have
lesions in other metabolic pathways criticallyinvolved in both
antiviral and growth inhibitory activities of IFN cannot be
excluded.
There are a variety of mechanisms unrelated to CAMP by
which IFN could conceivably inhibit cell growth. For exam-
ple, IFN significantly inhibits thymidine transport in L1210
cells. Indeed, it is for that reason that all the assays of cell
growth in this report utilized actual cell counts rather than
incorporation of3H-thymidine. IFN can also induce synthesis
of two cellular enzymes, 2',5'-oligoadenylate synthetase and
a cAMP-independent protein kinase (eIF2 kinase), which may
affect cellular RNA and protein synthesis (6, 7). A number of
cell lines including human fibroblastic tumor cells (28), mu-
rine leukemia (29), mouse embryonal carcinoma cells (30),
the Daudi human lymphoblastoid cell (31) and HEC-1 cells
(32) have been selected for resistance to the growth inhibitory
effects of IFN. While measurements of adenylate cyclase and
CAMP dependent protein kinase activity have not been re-
ported in these cells, induction of 2',5'-oligoadenylate syn-
thetase and a cAMP independent (eIF2) protein activity ki-
nase have. In some of the cell lines, e.g., L1210`, IFN has
neither antiviral activity nor the capacity to induce these
enzymes (29, 33). This cell has been shown to lack receptors
for IFN (27). In other IFN resistant cell lines, e.g., the IFN'
variant of RSa cells, embryonal carcinoma cells, Daudi cells,
2',5'-oligoadenylate synthetase activity may be normal (31,
34, 35). In some, e.g., RSa cells, Daudi cells, and HEC-1 cells,
the cAMP-independent (eIF2) protein kinase actively may be
present as well (28, 31, 32). Thus far there is no consistent
association between the levels of these two enzyme activities
and responsiveness to growth inhibitory activities of IFN.
The results presented here provide clear genetic and bio-
chemical evidence that the growth inhibitory effects of IFN,
at least in a murine macrophage cell line, are mediated by
cAMP. It will be ofinterest to examine adenylate cyclase and
cAMP dependent protein kinase activities in other IFN re-
sistant cell linesknown to have IFN receptors to establish the
generality of this phenomenon. Because the cell receptors for
IFNa and y appear to be distinct and independent, it will also
be important to learn whether the growth inhibitory activity
of IFNy, which on an antiviral unit basis may be more
profound than that of IFNO or a (36, 37), are mediated
through cAMP or by a different mechanism.
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